Patents by Inventor Owen Alexander Davis

Owen Alexander Davis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BCL6 INHIBITORS
    Publication number: 20230287003
    Abstract: The present invention relates to compounds of formula I that function as inhibitors of BCL6 (B-cell lymphoma 6) activity: wherein X1, X2, R1, R2, R30, R31 and Ring A are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated.
    Type: Application
    Filed: October 18, 2022
    Publication date: September 14, 2023
    Inventors: Benjamin Richard Bellenie, Kwai Ming Jack Cheung, Owen Alexander Davis, Swen Hoelder, Rosemary Huckvale, Gavin Collie, Mirco Meniconi, Alfie Brennan, Matthew Garth Lloyd
  • BCL6 inhibitors
    Patent number: 11512095
    Abstract: The present invention relates to compounds of formula I that function as inhibitors of BCL6 (B-cell lymphoma 6) activity: wherein X1, X2, R1, R2, R30, R31 and Ring A are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: November 29, 2022
    Assignees: The Institute of Cancer Research: Royal Cancer Hospital, Cancer Research Technology Limited
    Inventors: Benjamin Richard Bellenie, Kwai Ming Jack Cheung, Owen Alexander Davis, Swen Hoelder, Rosemary Huckvale, Gavin Collie, Mirco Meniconi, Alfie Brennan, Matthew Garth Lloyd
  • 2-quinolone derived inhibitors of BCL6
    Patent number: 11161839
    Abstract: The present invention relates to compounds of formula I that function as inhibitors of BCL6 (B-cell lymphoma 6) activity: Formula I wherein X1, X2, X3, R1, R2, R3, R4 and R5 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: November 2, 2021
    Assignees: The Institute of Cancer Research: Royal Cancer Hospital, Cancer Research Technology Limited
    Inventors: Benjamin Richard Bellenie, Kwai Ming Jack Cheung, Owen Alexander Davis, Swen Hoelder, Rosemary Huckvale, Matthew Garth Lloyd
  • 2-QUINOLONE DERIVED INHIBITORS OF BCL6
    Publication number: 20210206756
    Abstract: The present invention relates to compounds of formula I that function as inhibitors of BCL6 (B-cell lymphoma 6) activity: Formula I wherein X1, X2, X3, R1, R2, R3, R4 and R5 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated.
    Type: Application
    Filed: May 25, 2018
    Publication date: July 8, 2021
    Inventors: Benjamin R. Bellenie, Kwai Ming Jack Cheung, Owen Alexander Davis, Swen Hoelder, Rosemary Huckvale, Matthew Garth Lloyd
  • BCL6 INHIBITORS
    Publication number: 20210163497
    Abstract: The present invention relates to compounds of formula I that function as inhibitors of BCL6 (B-cell lymphoma 6) activity: wherein X1, X2, R1, R2, R30, R31 and Ring A are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated.
    Type: Application
    Filed: April 12, 2019
    Publication date: June 3, 2021
    Inventors: Benjamin Richard Bellenie, Kwai Ming Jack Cheung, Owen Alexander Davis, Swen Hoelder, Rosemary Huckvale, Gavin Collie, Mirco Meniconi, Alfie Brennan, Matthew Garth Lloyd
  • BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6
    Publication number: 20210147382
    Abstract: The present invention relates to compounds of Formula I that function as inhibitors of BCL6 (B-cell lymphoma 6) activity: wherein X1, X2, R1, R2 and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated.
    Type: Application
    Filed: May 25, 2018
    Publication date: May 20, 2021
    Inventors: Benjamin Richard Bellenie, Michael K. Carter, Kwai Ming Jack Cheung, Owen Alexander Davis, Swen Hoelder, Matthew Garth Lloyd, Ana Varela Rodriguez, Hannah Woodward, Paolo Innocenti